{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:38:13Z","timestamp":1793036293525,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating dosage of alemtuzumab during the first week and, thereafter, 30 mg intravenously 3 times per week for a maximum of 12 weeks. Trimethoprim\/sulphamethoxazole and valaciclovir prophylaxis was given to all patients. The overall response rate was 36% (5 of 14). Three patients achieved a complete remission (CR) and 2 patients a partial remission. The durations of the CRs were 2, 6, and 12 months, respectively. Toxicity included cytomegalovirus reactivation in 6 patients, which was successfully treated with ganciclovir or foscarnet; pulmonary aspergillosis in 2 patients; and pancytopenia in 4 patients. Epstein-Barr virus\u2013related hemophagocytosis was observed in 2 patients. Five patients died of causes related to the treatment, in combination with advanced disease. We conclude that alemtuzumab is active when used in patients with advanced, heavily pretreated PTL, although it is associated with significant hematologic toxicity and infectious complications. Further studies are warranted in younger patients and patients with less advanced disease. (Blood. 2004;103: 2920-2924)<\/jats:p>","DOI":"10.1182\/blood-2003-10-3389","type":"journal-article","created":{"date-parts":[[2004,1,5]],"date-time":"2004-01-05T20:12:45Z","timestamp":1073333565000},"page":"2920-2924","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":250,"title":["A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas"],"prefix":"10.1182","volume":"103","author":[{"given":"Gunilla","family":"Enblad","sequence":"first","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hagberg","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Erlanson","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Lundin","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Porwit","family":"MacDonald","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Repp","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Seipelt","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"O\u0308sterborg","sequence":"additional","affiliation":[{"name":"From the Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; Umea\u030a University Hospital, Umea\u030a, Sweden; Departments of Hematology\/Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden; Department of Medicine, University of Erlangen, Erlangen, Germany; Department of Medicine, University Hospital Carl Gustav Carcus, Dresden, Germany; and Department of Hematology\/Oncology, University Hospital, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222484738700_REF1","unstructured":"Jaffe ES, Harris NL, Stein H, Wardiman JW, eds. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. The World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001."},{"key":"2020021222484738700_REF2","doi-asserted-by":"crossref","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol.1998;16: 2780-2785.","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"2020021222484738700_REF3","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood.1998;92: 76-82."},{"key":"2020021222484738700_REF4","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabanillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphomas. Blood.1997;89: 4514-4520.","DOI":"10.1182\/blood.V89.12.4514"},{"key":"2020021222484738700_REF5","doi-asserted-by":"crossref","unstructured":"Blystad AK, Enblad G, Kvalo\u0308y S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant.2001;27: 711-716.","DOI":"10.1038\/sj.bmt.1702867"},{"key":"2020021222484738700_REF6","doi-asserted-by":"crossref","unstructured":"Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol.1994;47: 313-317.","DOI":"10.1136\/jcp.47.4.313"},{"key":"2020021222484738700_REF7","doi-asserted-by":"crossref","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath) as first line treatment for patients with B-cell chronic lymphocytic leukemia. Blood.2002;100: 768-773.","DOI":"10.1182\/blood-2002-01-0159"},{"key":"2020021222484738700_REF8","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood.2002;99: 3554-3561.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2020021222484738700_REF9","doi-asserted-by":"crossref","unstructured":"Dearden CE, Mateus E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood.2001;98: 1721-1726.","DOI":"10.1182\/blood.V98.6.1721"},{"key":"2020021222484738700_REF10","doi-asserted-by":"crossref","unstructured":"Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood.2003;101: 4267-4272.","DOI":"10.1182\/blood-2002-09-2802"},{"key":"2020021222484738700_REF11","doi-asserted-by":"crossref","unstructured":"Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD 52 in normal and leukemic B and T cells: correlations with in vivo therapeutic responses to Campath-1H. Leuk Res.1998;22: 185-191.","DOI":"10.1016\/S0145-2126(97)00158-6"},{"key":"2020021222484738700_REF12","doi-asserted-by":"crossref","unstructured":"Lundin J, O\u0308sterborg A, Brittinger D, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol.1998;16: 3257-3263.","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"2020021222484738700_REF13","doi-asserted-by":"crossref","unstructured":"Lundin J, Porwit-MacDonald A, Rossman ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia. Leukemia.2004;18: 484-490.","DOI":"10.1038\/sj.leu.2403258"},{"key":"2020021222484738700_REF14","doi-asserted-by":"crossref","unstructured":"Yao M, Cheng Ann-Li, Su I-J, et al. Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol.1994;87: 535-543.","DOI":"10.1111\/j.1365-2141.1994.tb08309.x"},{"key":"2020021222484738700_REF15","doi-asserted-by":"crossref","unstructured":"Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol.2002;44: 259-272.","DOI":"10.1016\/S1040-8428(02)00117-8"},{"key":"2020021222484738700_REF16","doi-asserted-by":"crossref","unstructured":"D'Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in non-lymphoblastic T-cell lymphomas and correlation with a poor prognosis. Blood.1996;87: 1045-1055.","DOI":"10.1182\/blood.V87.3.1045.bloodjournal8731045"},{"key":"2020021222484738700_REF17","doi-asserted-by":"crossref","unstructured":"Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood.1993;82: 807-812.","DOI":"10.1182\/blood.V82.3.807.807"},{"key":"2020021222484738700_REF18","doi-asserted-by":"crossref","unstructured":"Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol.2003;121: 913-918.","DOI":"10.1046\/j.1365-2141.2003.04385.x"},{"key":"2020021222484738700_REF19","unstructured":"Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW. A phase I trial of CD3\/CD28-activated T cells (Xcellerated T Cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res.2003;9: 3562-3570."},{"key":"2020021222484738700_REF20","doi-asserted-by":"crossref","unstructured":"Elfilein K, Rodriquez-Palmero, Kerkau M, Hunig T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood.2003;102: 1764-1770.","DOI":"10.1182\/blood-2002-11-3586"},{"key":"2020021222484738700_REF21","doi-asserted-by":"crossref","unstructured":"Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet.1999;354: 1691-1695.","DOI":"10.1016\/S0140-6736(99)02429-0"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/8\/2920\/1699101\/zh800804002920.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/8\/2920\/1699101\/zh800804002920.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:48:56Z","timestamp":1581547736000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/8\/2920\/18050\/A-pilot-study-of-alemtuzumab-antiCD52-monoclonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,15]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-10-3389","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,15]]}}}